61 completed, 7 terminated, 2 unknown, 1 recruiting. 22 Phase 3, 21 Phase 2, 21 Phase 4, 7 Not applicable, 3 Phase 1.
Follow Cinacalcet: new trials by email Literature Review of Cinacalcet trials Research Report on Cinacalcet
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism MT1013, Cinacalcet - Secondary Hyperparathyroidism, Chronic Kidney Disease | Phase 3 | Recruiting | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | 424 | 2025-09-30 | 2025-10-01 |
| The Trial of SHR6508 in Secondary Hyperparathyroidism SHR6508 plus oral placebo tablets, Cinacalcet plus intravenous placebo - Secondary Hyperparathyroidism | Phase 3 | Completed | Shanghai Hengrui Pharmaceutical Co., Ltd. | 498 | 2024-06-14 | 2025-12-12 |
| Parathyroid Hormone Level and Growth in Pediatric Patients With ESRD on Regular Hemodialysis Cinacalcet - Drug Effect | Phase 4 | Completed | Tanta University | 35 | 2023-08-05 | 2024-01-24 |
| A Study of SHR6508 in Secondary Hyperparathyroidism SHR6508, Cinacalcet - Secondary Hyperparathyroidism | Phase 2 | Unknown | Shanghai Hengrui Pharmaceutical Co., Ltd. | 75 | 2023-02-24 | 2023-06-18 |
| Novel Combination Therapy for Osteoporosis in Men Teriparatide or human parathyroid hormone (PTH) 1-34, Cinacalcet, placebo tablet - Male Osteoporosis | Phase 4 | Completed | VA Office of Research and Development | 40 | 2019-07-01 | 2026-09-03 |
| Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia KHK7580, Cinacalcet Hydrochloride - Secondary Hyperparathyroidism | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 404 | 2019-04-09 | 2022-04-25 |
| Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Etelcalcetide, Cinacalcet - Secondary Hyperparathyroidism, Chronic Kidney Disease | Phase 3 | Completed | Amgen | 637 | 2018-05-15 | 2021-04-30 |
| Bone Markers and Bone Density Changes in Hyperperparathyroid Dialysis Patients Under Cinacalcet Treatment Cinacalcet Tablets, calcitriol - Hyperparathyroidism; Secondary, Renal | Not applicable | Completed | Min-Sheng General Hospital | 40 | 2018-01-01 | 2020-11-19 |
| Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT Cinacalcet HCl - Hyperparathyroidism; Secondary, Renal | Phase 4 | Completed | Kyowa Kirin China Pharmaceutical Co., Ltd. | 750 | 2017-04-19 | 2024-04-29 |
| Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet. Cinacalcet 30 mg Tablet, Denosumab Inj 60 mg/ml, Placebo tablets - Primary Hyperparathyroidism, Parathyroid Adenoma | Phase 3 | Completed | Peter Vestergaard | 46 | 2017-03-01 | 2021-05-25 |
| Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism eplerenone, amiloride, Placebo - Primary Hyperparathyroidism | Phase 2 / Phase 3 | Completed | Brigham and Women's Hospital | 69 | 2016-01-01 | 2023-05-03 |
| Phase 3 Study of KHK7580 KHK7580, KRN1493 - Secondary Hyperparathyroidism | Phase 2 / Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 634 | 2015-09-01 | 2017-03-24 |
| Renal Osteodystrophy: An Individual Management Approach Alendronate, Teriparatide, Cinacalcet - Kidney Failure, Chronic | Not applicable | Completed | Hartmut Malluche, MD | 141 | 2015-07-01 | 2023-01-05 |
| Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis Cinacalcet - Secondary Hyperparathyroidism, Chronic Kidney Disease | Phase 3 | Completed | Amgen | 28 | 2015-06-10 | 2020-06-29 |
| Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis Cinacalcet HCl, Standard of Care - Chronic Kidney Disease, Secondary Hyperparathyroidism | Phase 3 | Terminated | Amgen | 55 | 2014-11-07 | 2020-06-29 |
| Phase 2 Study of KHK7580 Placebo, KHK7580 low dose, KHK7580 middle dose - Secondary Hyperparathyroidism | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 201 | 2014-07-01 | 2018-07-10 |
| Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions? Cinacalcet, parathyroid adenomectomy - Primary Hyperparathyroidism | Not applicable | Completed | Karolinska University Hospital | 110 | 2014-06-01 | 2024-08-06 |
| A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis ASP7991, Cinacalcet, Placebo - Secondary Hyperparathyroidism | Phase 2 | Completed | Astellas Pharma Inc | 62 | 2014-03-14 | 2024-11-06 |
| Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet Etelcalcetide, Cinacalcet, Oral Placebo - Secondary Hyperparathyroidism, Chronic Kidney Disease | Phase 3 | Completed | Amgen | 683 | 2013-08-13 | 2019-07-18 |
| Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism Cinacalcet hydrochloride, Standard of Care - Chronic Kidney Disease, Hyperparathyroidism, Secondary | Phase 2 | Terminated | Amgen | 18 | 2012-06-22 | 2020-06-17 |
Showing 20 of 72. Sign in to see all of them.
Hyperparathyroidism, Secondary (39) · Renal Insufficiency, Chronic (23) · Kidney Failure, Chronic (14) · Hyperparathyroidism, Primary (13) · Hyperparathyroidism (10) · Hypercalcemia (6) · Kidney Diseases (5) · Parathyroid Neoplasms (3) · Vascular Calcification (3) · Chronic Kidney Disease-Mineral and Bone Disorder (2) · Familial Hypophosphatemic Rickets (2) · Hypophosphatemia (2) · Neoplasm Metastasis (2) · Osteoporosis (2) · Anemia (1)
Amgen (35) · Kyowa Kirin Co., Ltd. (4) · Children's Mercy Hospital Kansas City (2) · Montefiore Medical Center (2) · Shanghai Hengrui Pharmaceutical Co., Ltd. (2) · Abbott (1) · Astellas Pharma Inc (1) · Brigham and Women's Hospital (1) · Centre Hospitalier Universitaire Vaudois (1) · Centre Hospitalier Universitaire, Amiens (1) · Chinese University of Hong Kong (1) · ENRICO VERRINA (1) · Hartmut Malluche, MD (1) · Istituto Auxologico Italiano (1) · Josep M Cruzado (1)
United States (21) · Italy (9) · Germany (8) · Poland (8) · Belgium (7) · France (7) · Hungary (7) · Russia (7) · Spain (7) · China (6) · Czechia (6) · Greece (5) · Portugal (5) · Switzerland (5) · Canada (4)
Maria Coco, MD, MS (2) · Aihua Zhang (1) · Aili Jiang (1) · Alp Ikizler, MD (1) · Anand Vaidya, MD MMSc (1) · Angela YM Wang, MD, PhD (1) · Anne F Cailleux, MD (1) · Bess Dawson-Hughes, MD (1) · Chaosheng Chen (1) · David M Spiegel, MD (1) · Dolores M. Shoback, MD (1) · Dominique de Quervain, Prof. MD (1) · Efstathios Mitsopoulos, MD (1)
PMID 20943783, PMID 15284307, PMID 15522938, PMID 15689407, PMID 15983958, PMID 16105056, PMID 17666472, PMID 17699221, PMID 18178780, PMID 18310602, PMID 18397701, PMID 18536954, PMID 18793528, PMID 19110359, PMID 19365139, PMID 19470620, PMID 19696213, PMID 19837909, PMID 22118402, PMID 22387567, PMID 22863242, PMID 23222688, PMID 23705925, PMID 24214232, PMID 24500308, PMID 24589316, PMID 25404192, PMID 25498379, PMID 25645432, PMID 25710802, PMID 25851955, PMID 25873267, PMID 25887067, PMID 26059012, PMID 26089029, PMID 27080930, PMID 28538380, PMID 29525393, PMID 31595982, PMID 32333877, PMID 34231877, PMID 35176038, PMID 36512619, PMID 36869794, PMID 38040277, PMID 40576086
2009 (2), 2008 (1), 2014 (1), 2016 (1), R01DK080770 (1)